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1. Introduction 
Imaging technologies form an inseparable part of molecular medicine and is a major 
research focus globally. Imaging of potential therapeutic or diagnostic agents in animal 
models in the early stage of research is an important step towards pre-clinical and clinical 
trials in humans. The resent achievements in molecular biology, virology and 
nanotechnology provide a totally new approaches to deliver therapeutic agents to the 
patient starting from conventional small molecules to virus based gene therapy. This creates 
a need for better tools for the pharmaceutical research. Small animal imaging provides 
excellent method for development of new generation diagnostic and therapeutic agents. 
Modern transient medicine provides completely new approaches to the diagnosis and 
therapy of diseases. Aim of the research is to develop more specific and efficient agents with 
minimum side effects. Furthermore, early diagnosis of diseases and accurate follow-up is an 
important part of the therapy. These requirements have lead to the more complicated 
bioactive molecules and their carriers. Development and refinement of new bioactive agents 
like peptides, proteins, nanoparticles, cells or viruses to human drugs is challenged by the 
perplexities and instability of the complexes in vivo.  
Due to the complexity of new diagnostic and therapeutic agents, their biodistribution and 
pharmacokinetic profiles in vivo is difficult to predict. Besides toxicity which is one of the 
main concerns to conventional small pharmaceutical compounds, new agents have to face 
defense mechanisms like reticuloendothelial system (RES), immunological response and 
liver as well. Larger size may also affect to the bioavailability of the agent. To overcome 
these problems comparative biodistribution studies in vivo with potential candidates should 
be started in early phase of the development. 
Non-invasive imaging has become important part of the basic and applied research. It 
allows biodistribution studies within same animal in different time points and phases of the 
disease. This is important for accurate monitoring since variations between individuals 
should be minimized. In other words, using imaging applications more equal results may be 
achieved than with using traditional methods based on post mortem or dosing studies. 
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Imaging is done with fewer animals which is cost-effective and also in accordance to 3R 
principle (Russell & Burch 1959). Appropriate dose is also easier to evaluate since behavior 
of the studied compound is immediately seen and changes can be done in relative short time 
interval compared to dosing studies which may last several months before any effects or 
results are obtained. 
In pharmacological aspect several in vivo modalities for small animal imaging exist today. 
Magnetic resonance imaging (MRI) and resonance (MRS), single photon emission computed 
tomography (SPECT), positron emission tomography (PET) and optical imaging (OI) are 
widely used and several reviews (King et al. 2002, Gröhn & Pitkänen, 2007, Kagadis et al. 
2010, Snoeks et al. 2011) have been published about these techniques, their strengths and 
faults. Choosing the most suitable imaging application for a certain study depends of the 
prioritization of features. 
Our laboratory has experience to use wide range of targeting and carrier moieties in 
experimental animal imaging. In this review we discuss applications in different imaging 
moieties in development of novel diagnostic and therapeutic agents. 
2. Small animal imaging 
Small animal imaging provides a non-invasive method to study biodistribution and 
pharmacokinetics of novel bioactive agents in physiologically relevant environment. 
Dedicated imaging equipments for laboratory animals, mostly for rodents and rabbits, are 
available. Different imaging modalities produce information about anatomical structures 
and physiological processes. Using different modalities together and combining the 
information, the most accurate information of the function of studied agents with good 
anatomical reference is achieved. 
2.1 SPECT 
Single photon emission computed tomography (SPECT) is based on detection of gamma 
radiation from the studied object. Scanning of different projections from several angles enable 
three dimensional (3D) reconstruction and further analysis of the patient or animal from 
various planes and directions. Furthermore, using 2D planar imaging pharmacokinetics of the 
radiolabelled agents can be followed over the time in the same animal.  
There are several radiotracers which can be used in SPECT imaging. The most used are 
Technetium, Indium and Iodine. Since different tracers have different physicochemical 
properties, labeling of the molecules or living particles for imaging purposes requires 
knowledge in biochemistry, traditional chemistry and radiochemistry. 
Historically iodine radiolabels are the most used in biochemistry and cell biology. Over 30 
isotopes of iodine have been reported of which around ten has been evaluated for biomedical 
applications (Welch & Redvanly 2002). Choose of the isotope depends on the purpose of the 
study. 123Iodine decays with practical energy for imaging studies (159 and 127 keV), but its 
relative short half-life (13 hours) limits its usage to the transient biodistribution studies. The 
half life of 125I is 60 days but emission energy is only 36 keV, which makes it impractical for 
human studies but adequate for animal experiments, especially in mice. Its long half-life 
enables imaging studies for several weeks with single administration of the studied agent.  
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For the labeling Iodine is oxidated. The target molecule typically contains benzene ring with 
ortho-substitution which in the most cases is OH-group, like tyrosine in the peptides or 
proteins. Oxidated iodine reacts to the positions 3 or 5 or both of the benzene ring. Iodine is 
oxidated by chloramine-T, Iodogen or lactoperoxidase in direct chemical methods (Hunter 
& Greenwood 1962, Fraker & Speck 1978, Marchalonis 1969). The most convenient method 
for iodination of biologically active molecules is commercially available Iodo-Gen tubes, 
which are coated with an oxidative agent 1,3,4,6-tetrachloro-3-6-diphenylglycouril. Due to 
the high hydrophobicity, this toxic oxidative compound is insoluble to water based buffers 
and remains in the walls of test tubes enabling solid phase oxidation of Sodium Iodine 
(NaI). Biomolecules are Iodinated in aquatic environment. The method is optimal for 
sensitive molecules and the toxic compound remains on the solid phase.  
If the target molecule lacks a benzene ring, an additional radioiodinating reagent may be 
used. The most common and commercially available reagent is Bolton-Hunter reagent. This 
reagent is succinimidyl derivatized ortho-substituted benzene ring (N-succinimidyl-3-[4-
hydroxyphenyl]propionate) (Bolton & Hunter 1973, Zalutsky & Narula 1987, Vaidyanathan 
et al. 1997, Gabel & Shapiro 1978). It reacts with primary amines, which are common in 
bioactive peptides, proteins, viruses and cells enabling iodination position to the target 
molecule.  
Alternative methods for iodine tracers are 99mTechnetium (99mTc)and 111Indium (111In), which 
are the most used isotopes in nuclear medicine. However, these metals have to form 
complexes with donor ligands or chelates prior administration. If the molecule itself lacks 
chemical structures, which react with the metal as a ligand like sulphur fingers (Maret, 
2004), the molecule has to be chelated. Diethylenetriaminepentaacetic acid (DTPA) and 
1,4,7,10-tetraazacyclododecane-N,N',N,N'-tetraacetic acid (DOTA) are the most commonly 
used chelates in imaging. As with Bolton-Hunter reagent, these chelates are also available as 
bifunctional chelating agents (BCA) (Figure 1.) (Chakraborty & Liu 2010, Liu & Edwards 
2001).  
 
Fig. 1. Commonly used bifunctional chelating agents (BCA) in imaging. Isothiocyanate 
(S=CH=N-) reacts with primary amines in physiogical conditions allowing labeling of 
unstable peptides and proteins. A) Isothiocyanate DTPA and B) isothiocyanate DOTA.  
Chelates increase the molecular weight of the target molecule and may also change the 
overall charge. Due to the molecular weight they may cause steric hindrances and change in 
total charge within small molecules. For larger molecules like peptides and proteins the use 
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of chelates is more common. In some cases the use of the linker between chelating part and 
reactive part may have effect to the pharmacokinetic properties (Garrison et al. 2008, Qu et 
al. 2001). 
2.2 PET 
In positron emission tomography (PET) imaging positron emitters and the following 
annihilation, is used to measure radioactive accumulation or consumption in the object. 
Annihilation produces two gamma quanta of 511 electron volts, which are emitted to the 
opposite directions (180o). The gamma quanta are easily located by using a serie of stable 
gamma cameras around the animal. The advantage of the PET radiotracers is that 
radionuclides are incorporated in the molecule with minimal inference to the function of the 
pharmaceuticals. Also sensitivity in PET is superior to SPECT. One important limitation for 
PET resolution is that the localisation of positron emission is not the same that the place of 
annihilation. The distance between emission and annihilation depends of the energy of the 
particle and also the density of tissue, for example average range for 18F in water is 0.064 cm 
(Cherry 2003). 
Labeling of PET radiopharmaceuticals is complicated and requires on-site cyclotron and 
highly educated personnel. Due to the short half-lives of tracers the cyclotron facilities should 
be near the research laboratory. Only 18F has adequate long half-life that the delivery time can 
be hours not minutes. It’s also notable that even the half-lives of PET nuclides are shorter than 
SPECT nuclides the dose effect may be larger with PET nuclides since their emission energy of 
511 electron volts is much higher than those of conventional SPECT nuclides.  
In clinical PET studies 18F in deoxyglucose (FDG) is the most commonly used diagnostic 
molecule for the functional studies in tissues. Others, such as sodium 18fluoride, 
18fluorothymidine, 18fluoromisonidazole, and 64Cu-labeled diacetyl-bis N4-
methylthiosemicarbazone are under evaluation for clinical use (Vallabhajosula et al. 2011). 
2.3 CT 
The oldest imaging modality is based on X-rays describe first by Wilhelm Röntgen already 
on 1895 (Röntgen, 1896). Ever since x-rays has been used to produce two dimensional 
images. Today X-rays are used in 3D topographic imaging. In principle, CT unit consist of 
high-voltage x-ray tube and oppositely located detector. Both x-ray source and detector 
rotate around the animal and a 3D reconstruction of the target can be made. Contrast is 
based on the ratio of the radiation which is passed through and absorbed in the patient. In 
contrast to SPECT and PET where radiation comes from the patient, in CT radiation is 
produced in the imaging equipment and the fraction of radiation passing through the target 
is measured. Since differences in linear attenuation coefficients for soft tissues are small 
(water = 0.21 cm-1; lean tissue = 0.20 cm-1; fat = 0.18 cm-1; bone 0.38 cm-1), contrast in the soft 
tissues is limited with x-ray based CT technique. Also increased resolution in CT raise 
significantly the radiation dose. 
Although x-ray based CT is not optimal for small animal imaging this method facilitates the 
localization of labeleld molecules in biodistribution studies. Today there are few 
manufacturers, which provide combined SPECT/CT and PET/CT equipments for clinical 
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use but also dedicated animal devices are on the market (Picler et al. 2008, Golestani et al. 
2010). The advantage of these multimodality systems is the ease of imaging with different 
modalities without moving the object and hence the co-localization of images can be 
performed easily (Figure 2). 
 
Fig. 2. Combined SPECT/CT images of mouse. A) 99mTc labeled commercially available 
bisphosphonate, Etidronate. Biodistribution profile studied in healthy mouse 30 min after 
i.v. injection. Etidronate accumulates mainly to the spine and joints of the hind limb. The 
image also visualizes the elimination of Etindronate through the kidneys and further 
excretion to the bladder (red accumulation). B) 111In labeled monoclonal antibody mF4-31C1 
against vascular endothelial growth factor receptor 3 (VEGFR-3) in ovarian carcinoma 
mouse model. Biodistribution profile studied 48 h after the single intra venous (i.v.) 
injection. Most of the antibodies are excreted through the liver. Signal in the lower part of 
the body indicates antibody’s accumulation in the tumor area and the upper signal 
represents remote activation of VEGFR-3 in metastatic lymph nodes (Huhtala et al. 2010). 
2.4 MRI/MRS 
The best modality for high contrast soft tissue anatomical imaging is magnetic resonance 
imaging (MRI). It is based on nuclear magnetic resonance (NMR) and the nature of proton 
nucleus. Isotopes that contain an odd number of protons and/or neutrons and have an 
intrinsic magnetic moment and angular momentum, like 13C, 2D, 15N and 31P can be used for 
MRI. When an isotope with magnetic properties (usually a proton) is in a strong magnetic 
field, the nucleus of the isotope is aligned with the magnetic field. When using a short 
radiofrequency (RF) pulse, the nucleus will align itself with the magnetic field. After the 
pulse, the nucleus will return on its natural state at certain rate called relaxation time, 
emitting an RF signal which is recorded. The RF signal is analyzed and used to produce MR 
image. Since the environment of the proton affects strongly to the relaxation time, contrast is 
achieved between tissues. Furthermore, using Magnetic Resonance Spectroscopy (MRS) 
analyses the relative concentrations of molecules in the target tissue can be estimated 
(Liimatainen et al. 2006b, Liimatainen et al. 2006a). 
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In MRI fine structure investigation and spectroscopy of the tissues is performed without any 
tracers but biodistribution studies of active compounds are followed using contrast agents. 
It’s notable that in small animal imaging, MRI is typically suitable to image certain part of 
the body and only local biodistribution e.g. the brain areas are imaged. Ferric, gadolinium or 
manganese are common contrast agents Ultra small superparamagnetic iron oxide (USPIO) 
particles, size range of 10 – 50 nm, are widely used for various applications like vascularity 
and macrophage content in atherosclerotic carotid plaques (Metz et al. 2011), lymph node 
metastasis (Lei et al. 2010), tumor vascular morphology and blood hemodynamics 
(Gambarota et al. 2010), diffusion in the brain disorders (Chin et al. 2009, Vellinga et al. 
2009), cell number quantification (Cheung et al. 2006) and oncological studies (Gambarota et 
al. 2006, Baghi et al. 2005, Keller et al. 2004).  
For the labeling several surface activated USPIO particles are available. The surface may 
contain chemically active groups like carboxylic acid, primary amines, aldehydes or 
isothiocyanates. Also biotinylated or avidin/streptavidin coated particles are available. 
Since biotin-avidin complex is one of the strongest found in nature, this phenomena can be 
used widely for various targeted applications or as a conjugation techniques. It should be 
noted that USPIO nanoparticles are several magnitudes larger than bioactive molecules and 
may cause sterical hindrances.  
For MRI studies gadolinium and mangansese based contrast agents have also been used. 
They require, like Technetium and Indium, chelates for labelling. Gadolinium ion as a water 
soluble salt is also quite toxic to animals and chelating reduces significantly its toxicity. 
However, the sensitivity of these contrast agents in MRI or MRS is significantly lower than 
corresponding radioactive metals in SPECT or PET techniques. In MRI millimolar 
concentrations are needed whereas nano and even picomolar concentration of radionuclides 
gives reliable SPECT or PET imaging results.  
Combination of PET/MRI is relatively new and rare hybrid scanning technique but very 
fascinating (Pichler et al. 2008, Bisdas et al. 2010, Antoch & Bockisch 2009). Especially in brain 
imaging combination of PET and MRI seems advantageous and promising (Heiss 2009). With 
combined PET and MRI imaging gives valuable information about function of the heart (PET) 
and also information about ventricular structure of the heart (MRI) (Nekolla et al. 2009). 
Combination of SPECT and MRI is available only for animal studies (Goetz et al. 2008). 
2.5 Optical imaging 
Compared to previously described methods advantaged of optical imaging (OI) include 
relatively ease usability, inexpensiveness and no need of radioactive tracers. In OI the 
detection is based on produced light from the tissues and monitored by common CCD 
camera. This method has been used for pharmacokinetic studies, angiogenesis, cancer, 
evaluating biodistribution or biological activity of potential therapeutic agents but also 
visualization of living embryos (Baker 2010, Dufort et al. 2010b, Penet et al. 2010, 
Eisenblatter et al. 2010, Canaria & Lansford 2010).  
The OI modality uses either fluorescence of bioluminence as a tracer. The molecules are 
typically labelled with fluorescent molecules and their biodistribution is followed like in 
SPECT or PET modalities (Weissleder & Ntziachristos 2003, Napp et al. 2011). The labelling 
chemistry is similar as with chelates. Several fluorescence molecules like fluorescein or 
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cyanine based molecules (Cy3, Cy5 etc.) may contain either amino or carboxylic acid groups 
or are pre-activated with succinimides, maleimimides or isothiocynanates for the 
conjugation. Another fluorescence method is based on green fluorescence protein (GFP). 
Using cells transfected with GFP gene, the function of the cells can be studied (Chudakov et 
al. 2005). However using fluorescence the depth of imaging target, surface reflectance, 
absorption, scattering and autofluorescence limit the sensitivity in true 3D imaging (Dufort 
et al. 2010a, Welsh & Kay 2005, Bremer et al. 2003).  
The light emission in bioluminescence is more sensitive, mainly because it is not interfered 
by autofluorescence since it is based on or oxygenation of Luciferin by Luciferase enzyme. 
During the oxygenation Luciferin substrate produces a photon, which is measured. As with 
GFP the function i.e. proliferation or cell death can be studied by using transfection with 
Luciferase gene. Transfected cells are inoculated to the experimental animal and followed 
over the time with Luficerin injections. After systemic injection, luciferin circulates and 
internalizes in to the cells. In Luciferase expressing cells the light is lit and can be imaged. 
This method has successfully use i.e. in imaging of the therapeutic effect of the viruses in 
cancer (Heikkilä et al. 2010). 
Another fascinated optical imaging application is splice correction method developed by 
Kole and his colleagues in 1998 (Kang et al. 1998). This method is based on transfection of a 
plasmid containing mutated Luciferase gene. This mutation causes an aberrant splicing of 
the pre-mRNA resulting non-functional mRNA. Upon the treatment with slice correcting 
oligonucleotide , which has complementary structure to the mutation site, the aberrant 
splicing is corrected and active Luciferase enzyme is expressed. This method has 
successfully used in cell cultures to study oligonucleotide internalisation in to the nucleus 
using cell penetrating peptides (CPP) (Mäe et al. 2009), but in the future it may have several 
applications in in vivo optical imaging. 
3. Therapeutic and diagnostic agents in imaging 
Although most of the pharmaceutical compounds are small and relatively simple structures, 
there are a growing number of other types of molecules for therapy and diagnostics. Exactly 
speaking it’s inaccurate to speak novel therapeutic molecules, since there are also other 
solutions to deliver the therapeutic agents and affect the target tissue or cells. In recent years 
nanoparticles (NP), viruses and stem cells has been in focus. 
What is common aim in developing novel therapeutic or diagnostic agents? The first aim is 
to develop specific targeting to the pathological alterations in tissues or cells. Secondly, they 
should be multifunctional containing several biological or chemical structures like targeting, 
drug, carrier and tracer moieties. Thirdly, the side effects should be minimized. Gene 
technology provides totally new approach to therapeutic field by delivering genes to the 
host cell, which transcription and translation machinery is used as "drug factory". 
Small animal imaging methods are ideal to study biodistribution of various types of 
molecules or even viruses and cells. Since nano- and picomolar concentration of radiolabel 
gives adequate signal, small amounts of label is needed to preliminary results of the 
biodistribution, accumulation, pharmacokinetics and metabolic routes of the studied 
compound. Other advantages in imaging include smaller animal groups than traditional 
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pharmacological studies since whole body results can be achieved over the time in vivo 
without sacrificing the animals.  
3.1 Conventional pharmaceutical and imaging compounds 
Most of the commercially available pharmaceutical compounds are small molecules below 500 
Da and they typically lack homing properties but the effect is based on specific binding as an 
agonist or antagonist in the target tissue or cell. If small pharmaceutical compounds are used 
in imaging studies, in the most cases the tracer should be directly incorporated to the molecule 
structure like chemical labelling of Iodine for SPECT, with cyclotrone for PET or the molecule 
should have chelating properties, like bisphosphonates, if a radioactive metal is used.  
There are several small molecules used in diagnostic imaging. One widely used imaging 
agent is (-)-2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT or RTI-55). In SPECT and 
PET imaging it has been used as 123I labeled or 18F (FP-CIT) labeled to map distribution of 
dopamine transporters and serotonin transporters in the brain e.g. in Parkinson’s disease 
and supranuclear palsy (Zubal et al. 2007, Shaya et al. 1992, Shang et al. 2007, Staffen et al. 
2000, Seppi et al. 2006). 
For PET the small organic imaging agent 18FGD, a glucose derivate, which accumulation 
through the body is related to tissue glucose consumption. This phenomenon is utilized in 
several applications of brain, tumor and myocardial metabolism (Berti et al. 2010, Miletich 
2009, Chen & Chen 2011, Kopka et al. 2008). 18FGD is widely used especially in 
neurosciences including drug research and development. With 18FDG it’s possible to 
determine activation of certain brain areas and hence applications are numerous, e.g. the 
sensitivity of brain areas to drugs as well as behavioral and therapeutic effects of the drug 
(Welch & Redvanly 2002).  
99mTc is the most commonly used isotope in nuclear medicine. When it is conjugated with 
DTPA, it is used to measure functionality of the kidneys (Eckelman & Richards 1970), as a 
pyrophosphate or bisphosphonate for skeletal imaging (Thrall 1976) and with 
hexamethylpropyleneamine oxine (HMPAO, Ceretec™) for brain perfusion (Leonard et al. 
1986a). 111Indium, chelated to oxine is used in clinics to label white blood cells or platelets to 
study sites of acute inflammation and infection but also thrombocytopenia in vivo (Leonard 
et al. 1986b, Thakur et al. 1977, Thakur 1977, Rodrigues et al. 1999, Louwes et al. 1999). 
3.2 Peptides 
Although peptides and polypeptides have been used for therapeutic purposes already for 
over 80 years when insulin was taken in clinical use, only few novel peptide based drugs 
have been approved by FDA or EMEA. Most of the drugs are direct copies from nature like 
follitropin beta, which is a synthetic copy of follicle stimulating hormone (FSH) (Fares et al. 
1992, Shome et al. 1988). Second generation peptide drugs are modified from the original 
molecule or are part of the larger proteins. Octreotide is a long-acting octapeptide with 
pharmacologic properties mimicking those of the natural hormone somatostatin (Bornschein 
et al. 2009, Anthony & Freda 2009, Stajich & Ashworth 2006). Fuzeon (Enfuvirtide) is a 36 
residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. Enfuvirtide binds to the 
first heptad-repeat (HR1) in the gp41 subunit of viral envelope glycoprotein and prevents 
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the conformational changes required for the fusion of viral and cellular membranes. It 
interferes the HIV-1 molecular machinery at the final stage of fusion with the target cell. 
Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of 
the HIV-1 fusion machinery and displace them, preventing normal fusion. (Joly et al. 2010, 
McKinnell & Saag 2009, Makinson & Reynes 2009)  
The number of bioactive peptides , with potential therapeutic or diagnostic properties, will 
be increased due to new screening methods for novel peptides. Epitope scanning (Reece et 
al. 1994, Frank, 2002) and phage display libraries produce novel biologically active peptides 
with specific binding properties to target proteins such as receptors and proteases (Nilsson 
et al. 2000). Some of the identified peptides are highly specific to the receptors of the 
specialized tissues providing a possibility to use peptides for targeting (Laakkonen et al. 
2002). These peptides serve as lead molecules for development of molecules for tumour 
imaging and therapy.  
Both natural peptides and peptides characterized by phage display are sensitive to 
metabolic processes like protease activity. This limits their usefulness as diagnostic and 
therapeutic agents. Rationale design of chemical modifications to maximize enzymatic 
bioavailability while preserving the potency and specificity of the peptide is needed (Adessi 
& Soto 2002). Typically peptides are cyclised or the amino acid side chains or bridge 
structures are modulated by using unnatural structures called peptidomimetics (Pakkala et 
al. 2007, Pakkala et al. 2010). 
Peptides and their modifications are typically produced by using solid phase peptide 
synthesis method (SPPS). Today synthesis is made with automated synthesiser and the time 
to produce a peptide is relatively short and several companies provide synthesis services for 
reasonable price. For labelling an additional reactive amino acid like tyrosine or cysteine are 
easy to add to the sequence for further labelling or conjugation purposes.  
3.3 Proteins 
Unlike peptides proteins are large and contain secondary, tertiary and some cases even 
quaternary structures on which the biological activity is based. Due to their defined tertiary 
structure and size, they may be sensitive to the labelling and purification methods. 
Furthermore, the administration route, which is mainly the systemic injection, and 
immunological response limits the usefulness of the proteins as drug candidates.  
For the biodistribution studies the surface of the proteins contains several different 
chemically active amino acid side chains or polysaccharides, which can be used for labelling 
purposes. Typically proteins are labelled via the ortho-hydroxy benzene ring of tyrosine or 
via primary amino groups of either the amino terminus or the side chain of lysine. For the 
imaging purposes proteins are labelled with iodine or conjugated with chelates as 
previously described. After the conjugation proteins can be purified with conventional size-
exclusion chromatography, dialysis or ultrafiltration using physiological conditions. In 
addition, chelate conjugated proteins can be labelled with 99mTc or 111In without further 
purification steps (Helppolainen et al. 2007). 
One of the most used group of proteins for diagnostic and therapeutic purposes are 
monoclonal antibodies. Already 50 products have been passed the long and very expensive 
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way from the primary finding to the licensed drug (Biopharma, 2011). The limiting factors of 
antibodies are large size (150 000 Da) which may interfere penetration of the molecule to the 
target tissue and possible squeamishness. Large size can be bypassed with Fab1 or Fab2 
fragments of the antibodies or as in human therapy using humanized monoclonal 
antibodies. The advantage of antibodies is high affinity compared to other protein-ligand 
interactions but also relatively easiness and diversity of modification chemistry without 
losing the binding activity.  
Antibodies have been successfully used in cancer therapy. Cetuximab (Erbitux) is a 
humanized monoclonal antibody against epidermal growth factor receptor (EGFR) which is 
over-expressed in various cancers (Vincenzi et al. 2008, Rivera et al. 2008). It has been 
successfully used in the treatment of colon carcinoma in humans. Same antibody has been 
studied as versatile SPECT and PET imaging agent in several cancer models, e.g. malignant 
mesothelioma, prostate cancer, head-and-neck squamous cell carcinoma, ovarian carcinoma 
(Figure 2.), colon cancer and universally EGFR positive tumors (Nayak et al. 2011, 
Malmberg et al. 2011, Hoeben et al. 2011, Huhtala et al. 2010, Cho et al. 2010, Ping Li et al. 
2008). 
3.4 Viruses 
This very exiting approach is based on natures own gene delivery method. After delivery, 
modified virus in target cell begins to use cell’s natural amplification techniques to produce 
therapeutic molecules. Today there are both transient (Adenoviruses) and stable 
(Lentiviruses) viral delivery systems (Rissanen & Yla-Herttuala 2007, Mahonen et al. 2010, 
Lesch et al. 2009). 
Biodistribution studies using non-invasive imaging is an important part of the development 
of virus based therapeutic agents. Viruses for the therapy are modified, they are unable to 
multiply and additional therapeutic and/or reporter genes are added to the viral genome. 
Expressed reporter genes can be imaged by using radiolabelled ligands. Using 
sodiumiodine symporter (hNIS) gene together with cancer-specific human telomerase 
promoter, human colocarcinoma xengraft has been imaged using radiolabelled iodine with 
SPECT/CT in animal model (Merron et al. 2007). 
Fusion proteins composed of avidin and either macrophage scavenger or low-density 
lipoprotein receptors (LDLR) have been constructed in order to target biotinylated 
molecules to cells of desired tissues. Using adenovirus mediated gene transfer transient 
expression of the fusion protein on cell membrane was achieved (Lehtolainen et al. 2002, 
Lehtolainen et al. 2003). When biotinylated molecule binds to the fusion receptor, it is 
internalized into the cell. Local gene transfer to target tissues could be used as a universal 
tool to deliver therapeutic agents at systemic low concentrations. Using biotinylated tracers 
like biotin-DTPA or biotin-DOTA compelexes these cells can be imaged in vivo (Turhanen et 
al. 2011). 
An alternative method to study the biodistribution of the viruses is avidin expression on the 
surface of the viral particle. Their homing properties to the target tissue may be enhanced 
using biotinylated moieties like antibodies or peptides. For imaging purposes biotinylated 
radiotracer is conjugated on the virus surface and biodistribution of the labelled virus is 
followed by SPECT (Raty et al. 2007, Raty et al. 2006, Kaikkonen et al. 2009).  
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Homing properties of viruses can be modified with biochemical methods using hybrid 
peptide with poly-lysine spacer together with cyclic peptide HWGF (His-Tyr-Gly-Phe) 
which binds to membrane metalloprotein receptors, MMP-2 and MMP-9 (Koivunen et al. 
1999). This peptide has been conjugated with trasnglutaminase enzyme on the surface of 
Adenovirus. The use of enzyme for conjugation is gentle and do not decrease the infectivity 
of the virus. Conjugated receptor specific peptide enhanced the tropism of the virus in vivo 
in rabbits (Turunen et al. 2002). 
3.5 Living cells 
Nuclear medicine has been used to image leucocytes in infectious or inflammatory processes 
in vivo already over four decades. The techniques detect inflammatory processes to which 
leukocytes migrate, such as those associated with abscesses or other infection. During 1970’s 
a new cell membrane tropic radioactive compound was developed. 111In-oxine is a lipophilic 
complex and penetrates through cell membrane without interference of the membrane 
bound molecules like receptors. Penetration is unspecific and all cell types can be labelled 
(Thakur et al. 1977, Becker & Meller 2001). 
Stem cells are immature cells, which have regenerative potential in various diseases. 
Especially neurodegradative disorders have been in the focus due to the poor regenerative 
properties on neuronal cells. The regenerative properties of the stems cells have been 
studied in Parkinson disease (PS), amyotrophic lateral sclerosis (ALS), Huntington's disease 
and stroke (Lindvall et al. 2004). For in vivo biodistribution studies stem cells have been 
labelled either with paramagnetic nanoparticles and followed with MRI (Arbab et al. 2003, 
Frank et al. 2003) or with 111In-oxine (Figure 3.) for SPECT imaging (Lappalainen et al. 2008, 
Makinen et al. 2006). 
N
O
N
O
N
O
111-Indium
 
Fig. 3. 111Indium oxine i.e. Indium 111 oxyquinoline. Indium is coordinating three 
oxyquinoline molecules. Due to the relative high hydrophobicity Indium oxine penetrates 
directly but unspecifically into the cytoplasm of the target cells and do not bind to the 
surface proteins. 
Radiolabeling of living cells is probably the most challenging labeling process since several 
issues has to be considered. Firstly, labeling conditions have to be effective, mild, temperate, 
fast and without complicated purification steps. Secondly, aseptic techniques have to be 
followed and last, appropriate dose for the cell batch has to be evaluated avoiding too high 
dose for the cells. For these reasons labeling conditions must always plan carefully for each 
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different cell type according their usual cultivation techniques. If longer (i.e. over 24 h) 
biodistribution studies are measured, effect of the labeling to the viability of the cells in vitro 
during timescale is worth to analyze. This is important since only the nuclide is seen in in vivo 
imaging but no information is achieved about the absolute condition of the cells viability. 
3.6 Nanoparticles 
There have been invasion of basic nanoparticle research in biomedicine. Many therapeutic 
agents like small organic compounds, nucleic acids, peptides and proteins are unstable in 
vivo and novel delivery technologies should be developed to improve their pharmacokinetic 
properties. Development of nanoparticle based delivery could enable sustained and hence 
regular release of drug. If NPs are also targeted, in the ideal case they would concentrate to 
the desired area and allow sustained release of the drug to the circulation or locally if 
needed. This would be beneficial for the patient as fewer drug intakes, steadier effect of the 
drug and hence milder side-effects but maybe also economically cost-effective. 
The size range of nanoparticles is comparable to the viruses. Conventionally nanosized 
materials like polymeric nanoparticles, liposomes and micelles are prepared from organic 
materials although they have limited chemical and mechanical stability and inadequate 
control over the drug release rate (Arruebo et al. 2006). Today there are NPs made of 
inorganic materials like silica or silicon (Haley & Frenkel 2008, Salonen et al. 2008). 
Inorganic material allows the production of porous or mesoporous nanoparticles with 
particle size in range of 50 – 300 nm and the pore diameter in the range 5 – 50 nm. The 
porous structure allows high loading capacity for the therapeutic agents and/or tracers, like 
fluorescein, radioactive compounds or paramagnetic iron (Wiekhorst et al. 2006, Alexiou et 
al. 2006a, Alexiou et al. 2006b).  
Furthrmore, the transportation and release of the molecules can be controlled. Mesoporous 
silicon nanoparticles have also shown to be non-toxic and stable (Salonen et al. 2008, Brigger 
et al. 2002, Limnell et al. 2007, Salonen et al. 2004). The surface of the nanoparticles can be 
derivatized with chemically active groups like primary amines or carboxylic acids and 
conjugated with several biologically and chemically active molecules (Figure 4). Large 
surface area allows conjugation of several different molecules on the same particle. Using 
targeting moieties the tropism of NPs can be modulated (Kukowska-Latallo et al. 2005, 
Costantino et al. 2005). 
 
Fig. 4. Chemically modified surfcaes of the silicon based mesoporous nanoparticles for the 
conjugation of bioactive molecules. A) carboxylic acid derivatized nanoparticles and B) 
primary amino derivatized nanoparticles with alkane spacers. 
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4. Conclusions 
Several imaging modalities for small animal pre-clinical studies have been developed. 
Various modalities provide different information about biodistribution, pharmacokinetics 
and effect of potential therapeutic agents to the target tissues and cells. Using SPECT or PET, 
biodistribution of the labelled agents can be easily followed over the time in animals with 
high sensitivity. Due to high spatial resolution, chances in fine structure and furthermore 
chemical chances of the target tissue can be studied using MRI and MRS. Contrast of CT is 
not optimal for soft tissue studies in small animals in vivo but using combined images with 
SPECT and PET it facilitates the localisation of the labelled bioactive agents. Optical imaging 
provides an excellent tool for the viability studies of cells and tissues. Luciferase expression 
based on transfected cells or whole transgenic animal gives direct information of the gene 
activation, growth and the death of the cells in vivo. 
Today several new therapeutic and diagnostic agents are large and/or complexed structures 
especially viruses, stem cells and nanoparticles. Due to high variety of the structures in new 
agents, requirement of interdiscipline skills and collaboration starting from basic organic 
chemistry to virology and cell biology is required. Accurate information of the 
biodistribution and pharmacokinetics before clinical trials is needed. Using different 
imaging modalities and combining the information, excessive preliminary knowledge of 
behaviour and effect of the studied complexes in vivo can be achieved. 
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